CoChat
Sign Up
Cited by 35CAR-T cell therapy researchImmune Cell Function and InteractionMonoclonal and Polyclonal Antibodies Research

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Single VHH-directed BCMA CAR-NK cells for multiple myeloma

Open access
Ren, Quan, Zu, Yingling, Su, Hongchang, Lu, Qiumei, Xiang, Bin, Luo, Yanping, Zhang, Jishuai, Song, Yongping·2023·Experimental Hematology & Oncology
DOI 10.1186/s40164-023-00461-8PMC PMC10680242
Open this paper in CoChat — free accountOpen PDF

Abstract

Natural killer (NK) cells are promising alternatives for the production of “off-the-shelf” CAR products, posing a lower risk of cytokine release syndrome (CRS) than CAR-T cells. We synthesized four single VHH-directed anti-BCMA CARs, incorporating various intracellular regions (2B4 versus CD28) and hinge domains (CD28 versus IgG1) and ectopically producing IL-15. NK cells derived from peripheral blood (PB) were expanded ex vivo by K562-mbIL21 feeder cells. Stable CAR transduction was obtained through lentiviral transduction with the BaEV-Rless pseudotyped lentiviral vector. BCMA-CD28-IL15 CAR-NK cells with ectopic expression of IL-15 exhibited superior cytotoxicity were compared to BCMA-CD28 CAR-NK cells lacking IL-15 and BCMA-hIgG1-IL15 CAR-NK cells with an IgG1 hinge domain. We further assessed the cytotoxic capabilities of BCMA-2B4-IL15 CAR-NK cells with 2B4 intracellular domain. The BCMA-CD28-IL15 CAR-NK cells revealed stronger cytotoxicity and higher cytokine secretion against BCMA+ tumor cells than BCMA-2B4-IL15 CAR-NK cells in vitro. In the MM.1S-Luc mouse model, BCMA-CD28-IL15 CAR-NK inhibited the growth of tumor cells and prolonged mouse survival. These results show that the single VHH-directed BCMA CAR-NK cells exhibited remarkable specific killing ability, making them a potential candidate for immunotherapy in multiple myeloma treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40164-023-00461-8

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 BCMA-CD28-IL15-engineered NK cells showed enhanced antitumor activity compared to BCMA-CD28 CAR-NK cells. (A) Schematic diagrams of BCMA CAR-NK constructs. (B) The fold expansion curve of NK cells, BCMA-CD28-IL15 CAR-NK cells, and BCMA-CD28 CAR-NK cells. (C) BCMA CAR expression of NK cells on day 14. (D) The cytotoxic activity of BCMA-CD28-IL15 CAR-NK cells vs. BCMA-CD28 CAR-NK cells and ex vivo-expanded NK cells against MM.1S and Daudi cells using a lactate dehydrogenase release assay (n = 3; ****, P < 0.0001). The numbers of effector cells were calculated as CAR-positive cells. NK cells were used to adjust the different CAR-positive cells. (E) MM.1S and Daudi cells were cocultured with BCMA-CD28-IL15 CAR-NK cells, BCMA-CD28 CAR-NK cells, or NK cells at an E:T ratio of 1:2 for 24 h. IFN-γ, granzyme B, and IL-15 secretion in supernatants was measured by ELISA (n = 3; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001)
Fig. 1 BCMA-CD28-IL15-engineered NK cells showed enhanced antitumor activity compared to BCMA-CD28 CAR-NK cells. (A) Schematic diagrams of BCMA CAR-NK constructs. (B) The fold expansion curve of NK cells, BCMA-CD28-IL15 CAR-NK cells, and BCMA-CD28 CAR-NK cells. (C) BCMA CAR expression of NK cells on day 14. (D) The cytotoxic activity of BCMA-CD28-IL15 CAR-NK cells vs. BCMA-CD28 CAR-NK cells and ex vivo-expanded NK cells against MM.1S and Daudi cells using a lactate dehydrogenase release assay (n = 3; ****, P < 0.0001). The numbers of effector cells were calculated as CAR-positive cells. NK cells were used to adjust the different CAR-positive cells. (E) MM.1S and Daudi cells were cocultured with BCMA-CD28-IL15 CAR-NK cells, BCMA-CD28 CAR-NK cells, or NK cells at an E:T ratio of 1:2 for 24 h. IFN-γ, granzyme B, and IL-15 secretion in supernatants was measured by ELISA (n = 3; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001)CC BY · PubMed Central
Fig. 2 In vivo antitumor activity of BCMA-CD28-IL15 CAR-NK cells in the MM.1S-Luc transplanted NCG mouse model. (A) Schematic diagram of the mouse in vivo study. The NCG mice received an IV injection of 2.0 × 106 MM.1S-Luc cells on day 0. Nine days after tumor inoculation, the mice were randomly divided into three groups (n = 3 for the control and mock-NK groups; n = 4 for the BCMA-CD28-IL15 CAR-NK group) according to the average radiance of the bioluminescence imaging. The mice were intravenously administered cryoprotectant (a solvent control), mock-NK cells, and BCMA-CD28-IL15 CAR-NK cells on day 9. (B) Bioluminescence images on days 9, 13, 20, 27, and 34. (C) Statistical analysis of the bioluminescence intensity on different days (****, P < 0.001; ns, no significance). (D) Body weight of each group measured on different days (****, P < 0.0001; ns, no significance). (E) Kaplan–Meier survival curves of mice in vivo. A statistical analysis of survival between groups was performed using the log-rank test. Statistical significance in survival rates was obtained after Bonferroni correction for multiple comparisons (*, P < 0.05)
Fig. 2 In vivo antitumor activity of BCMA-CD28-IL15 CAR-NK cells in the MM.1S-Luc transplanted NCG mouse model. (A) Schematic diagram of the mouse in vivo study. The NCG mice received an IV injection of 2.0 × 106 MM.1S-Luc cells on day 0. Nine days after tumor inoculation, the mice were randomly divided into three groups (n = 3 for the control and mock-NK groups; n = 4 for the BCMA-CD28-IL15 CAR-NK group) according to the average radiance of the bioluminescence imaging. The mice were intravenously administered cryoprotectant (a solvent control), mock-NK cells, and BCMA-CD28-IL15 CAR-NK cells on day 9. (B) Bioluminescence images on days 9, 13, 20, 27, and 34. (C) Statistical analysis of the bioluminescence intensity on different days (****, P < 0.001; ns, no significance). (D) Body weight of each group measured on different days (****, P < 0.0001; ns, no significance). (E) Kaplan–Meier survival curves of mice in vivo. A statistical analysis of survival between groups was performed using the log-rank test. Statistical significance in survival rates was obtained after Bonferroni correction for multiple comparisons (*, P < 0.05)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 10

  1. Zhang Y, Zhou W, Yang J, Yang J, Wang W. Chimeric antigen receptor engineered natural killer cells for cancer therapy. Exp Hematol Oncol. 2023;12:70. · DOI
  2. Mazinani M, Rahbarizadeh F. New cell sources for CAR-based immunotherapy. Biomarker Res. 2023;11:49. · DOI
  3. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, et al. Naturally occurring antibodies devoid of light chains. Nature. 1993;363(6428):446–8. · DOI · Paper page
  4. Han L, Zhang J-S, Zhou J, Zhou K-S, Xu B-L, Li L-L, et al. Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory Multiple Myeloma. Leukemia. 2021;35(10):3002–6. · DOI
  5. Colamartino ABL, Lemieux W, Bifsha P, Nicoletti S, Chakravarti N, Sanz J, et al. Efficient and robust NK-Cell Transduction with Baboon Envelope Pseudotyped Lentivector. Front Immunol. 2019;10:2873. · DOI
  6. Liu S, Galat V, Galat Y, Lee YKA, Wainwright D, Wu J. NK cell-based cancer immunotherapy: from basic biology to clinical development. J Hematol Oncol. 2021;14:7. · DOI · Paper page
  7. Wang X, Yang X, Yuan X, Wang W, Wang Y. Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential. Exp Hematol Oncol. 2022;11:85. · DOI
  8. Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018;32(2):520–31. · DOI
  9. Xu Y, Liu Q, Zhong M, Wang Z, Chen Z, Zhang Y, et al. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies. J Hematol Oncol. 2019;12(1):49. · DOI
  10. Li Y, Hermanson DL, Moriarity BS, Kaufman DS. Human iPSC-Derived natural killer cells Engineered with chimeric Antigen receptors enhance anti-tumor activity. Cell Stem Cell. 2018;23(2):181–92. e5. · DOI

Cited by

Sorted by citations

See all 35

Metadata

Authors
Ren, Q., Zu, Y., Su, H., Lu, Q., Xiang, B., Luo, Y., Zhang, J., & Song, Y.
Affiliations
  • Zhengzhou University (CN)
  • Shenzhen Pregene Biopharma Co., Ltd. (China) (CN)
Corresponding author
Song, Yongping
ORCID
Venue
Experimental Hematology & Oncology
Publisher
Springer Science and Business Media LLC
Published
2023-11-27
Volume
12
Issue
1
Pages
98-98
ISSN
2162-3619 (ISSN-L)
DOI
10.1186/s40164-023-00461-8
PMC
PMC10680242
OpenAlex
W4389049606
Cited by
35
References
2
Citations by year
2026: 8 · 2025: 21 · 2024: 6
FWCI
4.25
Type
journal article
Language
en
Open access
Licence
Locations
  • Experimental Hematology and Oncology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Zhengzhou University
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Keywords
BCMA, multiple myeloma, CAR-NK cells, natural killer cells, CD28, 2B4, IL-15, hinge domain, lentiviral transduction, cytokine release syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Single VHH-directed BCMA CAR-NK cells for multiple myeloma. https://app.cochat.ai/papers/10.1186/s40164-023-00461-8
The paper
Ren, Q., Zu, Y., Su, H., Lu, Q., Xiang, B., Luo, Y., Zhang, J., & Song, Y. (2023). Single VHH-directed BCMA CAR-NK cells for multiple myeloma. Experimental Hematology & Oncology. https://doi.org/10.1186/s40164-023-00461-8